Navigation Links
Carmel Pharma Introduces PhaSeal Secondary Set (C60)
Date:10/31/2009

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs

Columbus, OH (Vocus) October 31, 2009 -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.

For safety and ease of use, the non-vented Secondary Set offers the following features:

 
  • Drip chamber (20 drops/mL)
  • Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
  • Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
  • DEHP-free PVC tubing (40 in.)

For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.

PhaSeal is more than a system for the safe handling of hazardous drugs. It's the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the "Gold Standard" in safe handling, PhaSeal's airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.

The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children's in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today's clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Emily Frydendal at 614-318-2635 or emily.frydendal (at) carmelpharma (dot) com.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3140064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
2. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
3. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
4. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
5. WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release
6. 5 Steps to Pharmaceutical Marketing Happiness
7. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
8. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
9. CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags
10. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
11. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Carmel Pharma Introduces PhaSeal Secondary Set (C60) 
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology: